Filament Health Corp. (FLHLF)

0.0377 -0.0035 (-8.50%) As of 11:37AM EDT. Market open.

Filament Health Corp.

4475 Wayburne Drive
Unit 210
Burnaby, BC V5G 4X4
Canada

https://filament.health

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 13

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Benjamin Lightburn	Co-Founder, CEO & Chairman	127.42k	N/A	1986
Andry Tjahyana	VP of Business Development	138.34k	N/A	N/A
Mr. Jonathan Conlin	Corporate Secretary & Director	N/A	N/A	1985
Mr. Steven Nguyen CPA	Interim Chief Financial Officer	N/A	N/A	N/A
Ms. Lisa Ranken	Chief Operating Officer	N/A	N/A	1984
Mr. Ryan Moss	Chief Science Officer	N/A	N/A	N/A
Ms. Anna Cordon	Vice President of Marketing & Communications	N/A	N/A	N/A
Mr. Jeff Fellows	Head of Regulatory	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.

Corporate Governance

Filament Health Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.